Introduction
Cell-cycle progression, especially through mitosis is tightly regulated, thus ensuring the fidelity of genomic replication. The accuracy of mitosis depends on three main regulatory mechanisms: subcellular localization of proteins, post-translational ubiquitin-mediated proteolysis, and reversible phosphorylations (Nigg, 2001; Reed, 2003) . These events are precisely choreographed by mitotic kinases in time and space. A complex of the cyclin-dependent kinase 1 (Cdk1; also known as Cdc2) and its partner cyclin B is the most studied of the mitotic kinase complexes that are the key regulators of eukaryotic cell cycle. In addition to Cdk1, emerging evidence indicates that yet other protein kinases are involved in the regulation of mitosis, such as the pololike kinases, NimA-related kinases (Nek), the Bub1 family, LATS-related kinases, and the Aurora family (Nigg, 2001) .
The first recognized enzymes of the Aurora family were Ipl1p from Saccharomyces cerevisiae and Aurora from Drosophila melanogaster, which are important for chromosome segregation, and for centrosome separation and bipolar spindle formation, respectively (Chan and Botstein, 1993; Glover et al., 1995) . This subfamily in mammals comprises Aurora-A, Aurora-B, and Aurora-C (Adams et al., 2001; Nigg, 2001) . All Aurora proteins contain a variable N-terminal domain, followed by a highly conserved catalytic domain and a distinctive short C-terminal extension. Among them, Aurora-A and Aurora-B have been extensively studied, and their three-dimensional architectures have been visualized by X-ray crystallography (Cheetham et al., 2002; Nowakowski et al., 2002; Bayliss et al., 2003; Sessa et al., 2005) .
Aurora-A and Aurora-B have distinct subcellular localizations and specialized functions (Andrews et al., 2003; Carmena and Earnshaw, 2003; Meraldi et al., 2004) . Aurora-A is transcriptionally upregulated during mitosis (Tanaka et al., 2002) and degraded after metaphase by the ubiquitin-mediated proteasome, which is promoted by the hCdh1-activated anaphasepromoting complex/cyclosome (Honda et al., 2000; Castro et al., 2002; Taguchi et al., 2002) . Aurora-A localizes to centrosomes and spindle microtubules proximal to centrosomes during mitosis. Aurora-A kinase activity is regulated by phosphorylation (Walter et al., 2000) , dephosphorylation (Katayama et al., 2001) and by association with the allosteric activators Ajuba , HEF1 (Pugacheva and Golemis, 2005) or TPX2 (target protein for Xenopus kinesin-like protein 2). The latter is prerequisite for targeting Aurora-A to spindle microtubules (Kufer et al., 2002) and is important for both activating, and protecting kinase from phosphatase activity (Bayliss et al., 2003; Eyers et al., 2003; Tsai et al., 2003) . Human Aurora-A elimination through small interfering RNA (siRNA) leads to centrosome dysfunction as a consequence of apoptosis Du and Hannon, 2004) , implicating Aurora-A in the regulation of centrosome maturation and mitotic microtubules.
Aurora proteins are frequently overexpressed in human cancers (Giet et al., 2005; Marumoto et al., 2005) , and Aurora-A has also recently been identified as a candidate low penetrance cancer-susceptibility gene (Ewart-Toland et al., 2003 . Although controversial, ectopically overexpressed Aurora-A can transform rodent cells (Bischoff et al., 1998; Zhou et al., 1998; Littlepage et al., 2002) . This kinase family thus has considerable potential as a molecular therapeutic target (Keen and Taylor, 2004; Sausville, 2004) . Recent crystallographic determinations of Aurora-A and Aurora-B have accelerated the search for and development of Aurora inhibitors. The small-molecule inhibitors of Auroras, such as ZM447439, Hesperadin and VX-680, have also helped facilitate further investigation and study of Aurora function (Ditchfield et al., 2003; Hauf et al., 2003; Harrington et al., 2004) . VX-680 shows potential as a therapeutic agent as it has anticancer activity in rodent xenograft models.
The present study shows that human Aurora-A is an arginine-directed kinase and defines the substrate specificity of the enzyme. We also developed phosphospecific antibodies against Thr288 within the activation loop. The important features of Aurora-A determined using these phospho-specific antibodies were as follows. The Thr288 residue is phosphorylated on duplicated centrosomes and on spindle microtubules proximal to the poles during mitosis for a short period in vivo, an Aurora-A Thr288 kinase(s) might be located upstream in addition to autophosphorylated Aurora, phosphorylated Aurora-A is associated with the negative regulator PP1, and phospho-specific monoclonal antibodies restrain Aurora-A kinase activity in vitro.
Results
Human Aurora-A is an arginine-directed kinase We found using a series of substrates based on the histone H3 phosphorylation site (residues 5-15) that human Aurora-B preferentially phosphorylates target peptides when arginine is located two residues upstream (the PÀ2 position) of the phosphorylatable serine, and that other residues between the P-2 and P þ 4 positions also influence phosphorylation efficiency (Sugiyama et al., 2002) . The catalytic domain of Aurora-A shares B85% overall sequence homology with Aurora-B and only three out of 26 residues lining the ATP-binding site vary between the two human kinases (Cheetham et al., 2002) , whereas some residues for substrate recognition (Knighton et al., 1991) are different (e.g., Leu289 in Aurora-A which is Met233 in Aurora-B for P þ 1 recognition, and Thr217 in Aurora-A which is Glu161 in Aurora-B for PÀ3 recognition). Therefore, the substrate specificity requirements of human Aurora-A were characterized as follows. We assayed the kinase activity in vitro of bacterially expressed recombinant Aurora-A (rAurora-A) towards a series of GST-fused histone H3(5-15) peptides, in which amino acids surrounding Ser10 were mutated (as summarized in Figure 1a ). We found that rAurora-A phosphorylated (Figure 1b, lane 6) , but not the phosphorylation site mutant S10A (in which Ser-10 was changed to alanine) (Figure 1b, lane 7) , confirming the results of our immunoblot analysis using antiphospho-histone H3 (pSer10) antibody (Supplementary Figure 1a , lower panel). Phosphate was not incorporated when we used R8A as the substrate (Figure 1b , lane 3). Changing the arginine residue at the PÀ2 position to lysine significantly reduced the phosphorylation efficiency of rAurora-A (Figure 1b , lane 4), suggesting that arginine (and not simply any basic residue) at the PÀ2 position is important for optimal phosphorylation as it is in Aurora-B. Furthermore, the relative phosphorylation efficiency of Aurora-A produced in mammalian cells and in E. coli for the substrates was comparable (data not shown).
The phosphorylation efficiency of Aurora-A for T11A was about 20% of the wild type ( Figure 1b, lane 8) . To determine whether the phosphorylation of Thr11 by Aurora-A or the manipulation of T11A could influence phosphorylation efficiency of Ser10, 32 P-labeled GST-H3(5-15) was resolved by sodium dodecyl sulfate (SDS)/polyacrylamide gel electrophoresis (PAGE) and totally hydrolyzed with acid. Two-dimensional electrophoresis/chromatography of the corresponding radioactive hydrolysis products revealed only radioactive phosphoserine, whereas phosphothreonine and phosphotyrosine were undetectable (Figure 1c) . Thus, human Aurora-A phosphorylates GST-H3(5-15) at Ser10 in vitro and amino-acid residues at positions PÀ2 to P þ 1 are primarily important for phosphorylation by human Aurora-A.
To understand the downstream regulation of Aurora-A in relation to the signaling pathway of prolinedirected kinases such as Cdk1 or mitogen-activated protein kinase (MAPK), we further evaluated whether Aurora-A can phosphorylate substrates with proline at P þ 1. The phosphorylation efficiency of both Aurora-A and Aurora-B for GST-H3(5-15) (T11P) was about 5% of the wild type (Figure 1d , lanes 3 and 6), suggesting that the human Aurora protein kinase family does not cross-regulate proline-directed kinase signaling through the same phosphorylation sites.
Mutations in the activation loop of Aurora-A affect Aurora-A kinase activity Many kinases are phosphorylated in the activation loop between catalytic subdomains VII and VIII (Nolen et al., 2004) . For example, mitogen-activated kinases such as extracellular-signal regulated kinase (ERK)1 are phosphorylated and activated by a mitogen-activated kinase kinase in the TXY motif, whereas protein kinase A (PKA) is activated by autophosphorylation in the activation loop (Johnson et al., 1996) (Figure 2a ). Three serine/threonine residues (Ser283, Ser284, and Thr288) that might serve as potential phosphorylation sites predicted by the NetPhos 2.0 Prediction Program (http://www.cbs.dtu.dk/services/NetPhos/) lie within the Aurora-A activation loop between the DGF (subdomain VII) and PPE (subdomain VIII) residues. To determine whether any of these amino acids play a role in Aurora-A kinase activity, each one was independently mutated to alanine (S283A, S284A, and T288A). The recombinant mutant kinases were assayed to determine whether they abrogated kinase activity toward . Figure 2b shows that mutant S283A retained approximately normal kinase activity, whereas mutants S284A and T288A had none. The kinase-dead form (KN, K162R) of Aurora-A retained B5% of wild-type activity, consistent with the result of the Xenopus Aurora-A K169R equivalent mutant (Haydon et al., 2003; Eyers and Maller, 2004) . These results suggest that the activation loop plays a key role in Aurora-A kinase activity and that the Ser284 and Thr288 residues are crucial for this process. These data also confirmed that purified rAurora-A was free of contaminating bacterial kinase(s). Although phosphorylation of the kinase activation loop is a prerequisite for substrate recognition by some kinases, the negatively charged residue glutamate or aspartate could not functionally and structurally substitute for the Thr288 residue to allow normal substrate recognition and kinase activity of human Aurora-A (Figure 2b , supplementary Figure 2 , and data not shown).
Thr288 of Aurora-A is the consensus phosphorylation site for Aurora-A, but Aurora-A is not a major Thr288 kinase The Thr288 of Aurora-A conformed to the consensus phosphorylation site for Aurora-A itself. To determine whether or not Aurora-A phosphorylates Thr288 Phospho-regulation of Aurora-A S Ohashi et al in vitro, we constructed a series of GST-fused activation loop peptides of the Aurora family kinases as substrate, as summarized in Figure 3a . Figure 3b shows that rAurora-A phosphorylated significantly more GST-AA(281-293) than GST-H3(5-15) in vitro. However, the phosphorylation efficiency of rAurora-A for GST-AB(225-237) and GST-AC(188-200) was about 15% of that for GST-AA(281-293). These results indicated that the surrounding residues (e.g., the PÀ4, PÀ1 or P þ 1 residue) generated specificity and that GST-AA(281-293) served as a good substrate for human Aurora-A in vitro.
To estimate the influence of these surrounding residues on substrate specificity, we mutated individual sites to alanine within the GST-AA(281-293) ( Figure 3c ) and then examined their ability to act as substrates for rAurora-A in vitro. The T288A mutant was not essentially phosphorylated by rAurora-A ( Figure 3d , lane 8), thereby confirming this residue as the in vitro phosphorylation site of Aurora-A. When R286A was the substrate, the phosphorylation efficiency of rAurora-A was obviously reduced (Figure 3d , lanes 6). This is consistent with the finding that arginine at the PÀ2 position is strictly required as described above. The phosphorylation efficiency of rAurora-A for S283A, S284A and T287A was negligibly reduced, indicating that these residues are not the phosphorylation sites in vitro. The Thr287 of RRT 287 T 288 also lies within the minimal Aurora phosphorylation motif RXT, but was not practically phosphorylated by Aurora-A in vitro. This result agrees with the mass spectrometry findings (Supplementary Figure 1b) . Although not comparable with GST-H3(5-15), the R285A point mutation (arginine at the PÀ3 position to alanine substitution) led to a significant decrease in the phosphorylation rate, indicating that the preceding arginine of two arginine residues (at PÀ3 and PÀ2) is also key to phosphorylation.
In addition to evaluating substitutions to alanine within the activation loop as outlined above, we also characterized the influences of individual substitutions to lysine at positions 285, 286, and 287 ( Figure 3e ). The phosphorylation efficiency of rAurora-A for R285K (at the PÀ3 position) was about 20% of the wild type ( Figure 3f , lane 3). When R286K was the substrate, phosphate was not incorporated. These results confirmed the primary importance of two adjacent arginine residues (at the PÀ3 and PÀ2 positions) for phosphorylation. We changed the threonine residue at the PÀ1 position to lysine, T287K (RRK287T), which mimicked the human Aurora-B and -C sequence ( Figure 3a ). This manipulation increased the phosphorylation efficiency of Aurora-A ( Figure 3f , lane 5). This result suggested that preferential phosphorylation of GST-AA(281-293) over GST-AB(225-237) and GST-AC(188-200) ( Figure 3b ) is responsible for the residue at the P-4 or at the P þ 1 position of the substrate. Mutating the target Thr288 to Ser did not obviously alter phosphorylation efficiency ( Figure 3f , lanes 2 and 6), suggesting that Aurora-A can phosphorylate serine as well as threonine.
To determine whether the major Thr288 kinase is Aurora-A per se, HeLa cell lysates were immunodepleted with anti-phospho-Aurora-A antibody and in vitro kinase assay towards substrate GST-AA(281-293) was analyzed. We used a rabbit polyclonal antibody against phospho-Aurora-A that could remove all endogenous activated Aurora-A protein from the extracts ( Figure 3g , lanes 2 and 4). Thr288 phosphorylation activity was not abrogated in the resulting supernatants ( Figure 3h , lanes 6 and 8). Similar results obtained after immunodepleting Aurora-A from nocodazole-treated HeLa cell lysate using the Aurora-A antibody agreed with this finding (Figure 3h , lanes 2 and 4). These results suggest that an upstream kinase(s) activity of Aurora-A is functional in cells in addition to autophosphorylation.
Generation of monoclonal antibodies against human phospho-Thr288 Aurora-A Immunostaining with polyclonal antibodies sometimes produces variable results. We therefore developed monoclonal antibodies against human phospho-Thr288 Aurora-A to visualize Aurora-A activation in cells (Supplementary Figure 3) . We first determined whether phospho-Aurora-A was nocodazole-specific or mitosisassociated as follows. The phosphorylation status of Thr288 was directly monitored with Aurora-A Kinase activities of wild-type and mutated rAurora-As were assayed in the presence of g 32 P-ATP using GST-H3(5-15) as substrate. Samples were separated on polyacrylamide gels, stained, dried, and visualized by autoradiography. Upper panel, autoradiograph shows phosphorylated GST fusion protein; middle and lower panels, Coomassie blue staining shows total amounts of substrate and kinases, respectively. (c) Wild-type or Thr288 mutants of glu-Aurora-B were transiently expressed in COS cells under conditions indicated at top of panels. In vitro kinase assay of glu-Aurora-B immunoprecipitates (upper panel) and Coomassie blue staining in middle and lower panels shows total amounts of kinases and substrate, respectively. 
GST Phospho-regulation of Aurora-A S Ohashi et al expression in HeLa cells synchronized by doublethymidine block-release from the G1/S boundary, and the cell cycle was concomitantly monitored by FACS analysis (data not shown). Consistent with the earlier findings, Aurora-A protein that was undetectable or detected at very low levels during G1 began to accumulate during S phase, peaked at mitosis, and then abruptly declined ( Figure 4A , upper panel). PhosphoAurora-A was detectable only for a short window during mitosis ( Figure 4A , lower panel), and did not coincide with the period of Aurora-A expression. These results indicated that Aurora-A activation was generally associated with mitosis and was not a stress response to nocodazole, and that Aurora-A activation and expression levels per se were not associated. Based on these results, phospho-Aurora-A localization during mitosis was determined by indirect immunofluorescence with the monoclonal anti-phospho-Aurora-A antibody pA7.2 ( Figure 4B ). The phospho-Aurora-A signal was initially weak but significant on duplicated centrosomes during the G2 phase ( Figure 4B, panel a) . The level of phospho-Aurora-A was maximal at the two spindle poles and on the microtubules proximal to the poles at metaphase ( Figure 4B, panel b) . When cell division entered anaphase, phospho-Aurora-A staining abruptly diminished ( Figure 4B , panels c-f). These immunofluorescence results were consistent with the brief window of phospho-Aurora-A detection by immunoblotting.
Exploitation of anti-phospho-Thr288 Aurora-A monoclonal antibodies We investigated how Aurora-A exerts kinase activity under association with the negative regulator PP1c (Supplementary Figure 4) . We initially explored whether the phosphorylated Aurora-A could form complexes with PP1c in vivo using the phospho-specific monoclonal antibody, to specifically immunoprecipitate phosphoAurora-A complexes. The phospho-specific pA7.2 antibody co-immunoprecipitated PP1a, indicating that phosphorylated Aurora-A associates with PP1c in vivo. PP1c is inactivated by the cell-cycle-dependent phosphorylation of serine/threonine residues in its carboxyl terminus by Cdk1/cyclin B (Dohadwala et al., 1994; Yamano et al., 1994; Kwon et al., 1997; Puntoni and Villa-Moruzzi, 1997) and Nek2 (Helps et al., 2000) . Therefore, we investigated whether PP1a immunoprecipitated by the phospho-Aurora-A antibody was phosphorylated at the Thr320 by Cdk1/cyclin B. Immunoblots using anti-phospho-PP1a (Thr320) antibody showed that PP1a immunoprecipitated by the phospho-Aurora-A antibody was phosphorylated at Thr320 (Figure 5a , lane 6, lower panel). Thus, activated Aurora-A forms complexes with PP1c phosphorylated at Thr320, which attenuates phosphatase activity by Cdk1/cyclin B.
Aurora-A is expressed at high levels in human cancer cells and in most human tumor cell lines (Marumoto et al., 2005) . Strategies targeting phospho-Aurora-A using monoclonal antibodies might therefore constitute an effective therapeutic approach to human cancer. The kinase activity of rAurora-A in vitro was dosedependently inhibited in the presence of monoclonal anti-phospho-Thr288 Aurora-A antibodies 7.2 and 12.1 (Figure 5b ), suggesting that both antibodies 7.2 and 12.1 represent excellent therapeutic candidates for cancer treatment.
Discussion
Accumulating evidence indicates that the activity of the Aurora protein kinase family is prerequisite for mitotic events from yeast to vertebrates. At present, at least 25 human protein substrates have been discovered, ranging from kinases through structural proteins to transcription factors. The physiologically relevant protein substrates, phosphorylation by which is demonstrably and directly related to mitosis, remain to be identified. Therefore, identification of the consensus sequence for Immunofluorescence staining for Thr288-phosphorylated Aurora-A protein expression in HeLa cells. Asynchronous HeLa cells growing on coverslips were fixed with methanol and stained with anti-pA7.2 monoclonal antibody for Thr288-phosphorylated Aurora-A (green). Weak but significant signals of phospho-Aurora-A were first detected on duplicated centrosomes during G2 phase (a, arrow heads). Level of phospho-Aurora-A was maximal on two spindle poles and on microtubules proximal to the poles at metaphase (b). When cell division entered anaphase, phospho-Aurora-A staining abruptly diminished (c-f).
Phospho-regulation of Aurora-A S Ohashi et al phosphorylation by the human Aurora enzymes might prove useful in further identification of the phosphorylation site(s) of physiological substrates.
Substrate specificity
To prepare kinases with which to determinate substrate specificity, the first consideration when using an insect system is that of co-purifying cellular kinases and phosphatases. Because Escherichia coli lacks classical serine/threonine/tyrosine kinases and phosphatases (Kennelly, 2002) , host kinases and phosphatases that co-purify with the target kinase are not a major concern. The second consideration is that of the phosphatase inhibitor, okadaic acid. (Bayliss et al., 2003) . However, another study found that GST-Aurora-A, but not His 6 -tagged Aurora-A expressed in Sf9 insect cells possesses obvious kinase activity . These considerations are especially important when producing kinases for substrate specificity, so we expressed rAurora-A in bacteria. To ensure that the kinase activity of rAurora-A in this series of experiments was intrinsic to Aurora-A and not a result of an E. coli kinase(s) that might be contaminating the Aurora-A preparation, the in vitro reconstitution assay tested the ability of TPX-2, which belongs to the most extensively characterized Aurora-A module, to activate Aurora-A. The specific activity of rAurora-A was relatively low (64.3 nmol/min/mg), but it substantially phosphorylated Ser10 on GST-H3(5-15) (Supplementary Figure 1a and c). S284A, T288A, and T288E as well as the kinasenegative mutant (K162R) rAurora-A prepared using the same procedure as the wild type could not phosphorylate the same substrate (Figure 2b ). Furthermore, GST-TPX2(1-43) activated rAurora-A eightfold more than the GST moiety alone in the in vitro reconstitution assay (Supplementary Figure 1c) . These results revealed that bacterially expressed His 6 -tagged full-length human Aurora-A in this study was enzymatically and structurally active. Based on the sequences surrounding residues phosphorylated by budding yeast Aurora Ipl1p in a set of yeast kinetochore proteins, the generic and heretofore substrate sequence recognized by the Aurora family was Arg/Lys-X-Ser/Thr-Ile/Leu/Val, where Ser or Thr are the phosphorylatable residues, X is any amino acid, and Arg/Lys and Val/Leu/Ile denote a preference for basic and hydrophobic/aliphatic amino acids, respectively (Cheeseman et al., 2002) . The present results revealed that Arg (and not simply any basic residue) at the PÀ2 position is important for optimal phosphorylation by human Aurora-A. Indeed, alignment with fragments of reported phosphorylation sites within human Aurora-A substrates confirmed the preferred substrate epitope for Aurora-A phosphorylation as Arg-X-Ser/Thr-Leu/Val (Figure 6a ). Consistent with this finding, rAurora-A phosphorylated significantly more GST-AA(281-293) (the P þ 1 is Leu) than GST-H3(5-15) (the P þ 1 is Thr), GST-AB(225-237) (the P þ 1 is Met), and GST-AC(188-200) (the P þ 1 is Met) in vitro (Figure 3b ). We also indicated that Aurora protein kinases do not prefer the Ser/Thr-Pro motif that is targeted by proline-directed kinases such as Cdk1 or MAPK (Figure 1d ), suggesting that Aurora does not cross-regulate proline-directed kinase signaling through the same phosphorylation sites. It is important to understand the downstream regulation of the human Aurora family. While this manuscript was in preparation, Arg/Lys/Asn-Arg-X-Ser/Thr-B (where B denotes any hydrophobic residue with the exception of proline) has been reported as the Aurora-A consensus after a study using synthetic Phospho-regulation of Aurora-A S Ohashi et al peptide substrates (Ferrari et al., 2005) . Our present results are in close agreement with the findings of that study. Sequences surrounding phosphorylated sites of p53 (Ser315) and BRCA1 (Ser308) did not fall into the Aurora-A consensus motif. Correspondingly, GST-TPX2(1-43) does not contain the consensus motif, but nevertheless GST-TPX2(1-43) is indeed a substrate of the kinase in vitro (Supplementary Figure 1c, lane 2) . This observation is consistent with the previous results (Bayliss et al., 2003) . Therefore, these discrepancies indicate that these substrates contain other Aurora-Abinding sites besides the phosphorylation consensus motif that increase the local substrate concentration or alternatively, Aurora-A conformationally recognizes theses substrates, thus phosphorylating residues that do not display the consensus sequence. On the other hand, human Aurora-B also displayed a stringent requirement for Arg residue at the PÀ2 position (Sugiyama et al., 2002) , but alignment of human Aurora-B substrates showed a wider tolerance of the nature of the P þ 1 residues and a preference for arginine or lysine at the PÀ3 site (Figure 6b) . Given that the core kinase folds of human Aurora-A and Aurora-B were similar to those determined for PKA (Cheetham et al., 2002; Nowakowski et al., 2002; Bayliss et al., 2003; Sessa et al., 2005) and that these kinases have similar substrate specificity, the positions of Auroras that recognize substrates can be inferred from complexes of PKA with a pseudosubstrate inhibitory peptide (Knighton et al., 1991) . The PÀ2 Arg of the substrate contacts PKA at three Glu residues (Glu170, Glu203, and Glu230) that are conserved in human Aurora-A (Glu260, Asp294, and Glu321) and Aurora-B (Glu204, Asp 238, and Glu265), as well as in yeast Ipl1p (Glu231, Asp266, and Glu293), suggesting that substrates bind Auroras and PKA with the same orientation (Figure 6c ). Based on this assumption, the hydrophobic pocket of Aurora-A (Leu289, Leu293, and Leu296), which accommodates the side chain of the P þ 1 residue of the substrate, is conserved but less hydrophobic in Aurora-B (the first Leu289 in Aurora-A replaces Met233 in Aurora-B), possibly explaining the wider tolerance for the nature of the P þ 1 residues in Aurora B substrates (Figure 6c and d) . These taken together . Hydrophobic pocket of Aurora-A (Leu289, Leu293, and Leu296) that accommodates side chain of substrate P þ 1 residue is conserved but less hydrophobic in Aurora-B, with Met233 being replaced by a first Leu289 in Aurora-A. Aurora-A also contains ADP. Figures prepared using PyMOL software, where surface of P þ 1 pocket is colored according to atom type: nitrogen is blue, oxygen is red, and sulfur is orange. Carbon atoms and surface representation of other proteins is colored gray.
Phospho-regulation of Aurora-A S Ohashi et al with previous findings indicate that the canonical phosphorylation motifs in substrates recognized by human Aurora-A and Aurora-B are Arg-X-Ser/ThrLeu/Val/Ile and Arg-X-Ser/Thr (with the exception of proline in the P þ 1 position), respectively.
Thr288 phosphorylation
In most Ser/Thr kinase structures reflecting active enzymes, both the activation loop and helix aC are properly aligned for substrate and nucleotide binding (Nolen et al., 2004) . Upon phosphorylation of a specific residue within the activation loop, the protein kinase active site is reoriented to allow proper ATP and substrate binding, and Aurora-A is no exception. We confirmed that this residue is phosphorylated in vivo under physiological conditions using monoclonal antibodies specific to the phosphorylated Thr288 ( Figure 4A and B). The candidate kinase(s) that phosphorylates Thr288 and activates Aurora-A appears to be Aurora-A per se. The activation segment of Aurora-A contains the sequence Arg-Arg-Thr-pThr-Leu surrounding the phosphorylated Thr288 (which has a prefix 'p'). This sequence is compatible with the consensus recognition sequence for Aurora-A (Arg-X-Ser/Thr-Leu/Val/Ile) described above. Hence, autophosphorylation with Aurora-A is possible. Indeed, rAurora-A efficiently phosphorylates Thr288 in the activation loop of Aurora-A in vitro (Figure 3b and d) . Meanwhile, immunodepletion with anti-pThr288 Aurora-A antibody in HeLa cell lysates suggests that an unidentified upstream kinase(s) of Aurora-A phosphorylates the activation loop followed by autophosphorylation of Aurora-A at the site in vivo (Figure 3h ). This appears to be true of the activation loop of some protein kinase C (PKC) isotypes, which is phosphorylated through autophosphorylation in E. coli but the in vivo phosphorylation reaction depends on the universal PKC upstream kinase 1 (PDK1) (Newton, 2003; Xu et al., 2004) . There are precedents for this, given that Aurora-A can be phosphorylated in vitro at Thr288 by PKA (Walter et al., 2000) and by mitogen and stress-activated protein kinase (MSK1) . Thus, determining whether PKA or MSK1 is the major Thr288 kinase in vivo would begin to address the Aurora-A signaling pathway. PAK1 was recently identified as one candidate for in vivo upstream kinase(s) (Zhao et al., 2005) . A contribution from other kinases cannot be ruled out. Much remains to be determined to indicate whether the pathway is primarily regulated by autophosphorylation with the allosteric activators of Aurora-A or whether an in vivo upstream kinase(s) of Aurora-A is responsible for the Thr288 phosphorylation. Therefore, we intend to identify the putative upstream kinase(s) that underlies Aurora-A activation.
Anti-phospho-Thr288 monoclonal antibodies
The phosphorylation site-specific monoclonal antibody pA7.2 allowed the time course of endogenous Aurora-A activation in HeLa cells to be determined and the elucidation of temporally and spatially restricted activation during prometaphase and metaphase on duplicated centrosomes and on spindle microtubules proximal to the poles in vivo ( Figure 4A and B) rather than the concomitant expression level of Aurora-A per se. Moreover, using the phospho-specific pA7.2 monoclonal antibody, we investigated the potential regulatory relationship between Aurora-A activation and PP-1c inactivation. The results showed that activated Aurora-A forms complexes with PP1c phosphorylated at Thr320, which attenuates phosphatase activity (Figure 5a ), suggesting that PP1 activity is downregulated at the onset of mitosis as a result of phosphorylation by Cdk1/cyclin B or other protein kinases. Finally, we discovered that phospho-specific monoclonal antibodies inhibited the in vitro kinase activity of rAurora-A (Figure 5b ), setting the stage for future development of useful therapeutic agents for use in the treatment of cancer.
In conclusion, this study found that the consensus phosphorylation motifs of human Aurora-A and Aurora-B are Arg-X-Ser/Thr-Leu/Val/Ile and Arg-XSer/Thr (with the exception of Pro in the P þ 1 position), respectively. We also developed phospho-specific antibodies against Thr288 within the activation loop and demonstrated the importance of Thr288 phosphorylation in regulating the level of Aurora-A kinase activity during the cell cycle in vivo.
Materials and methods

Materials
Anti-phospho-specific histone H3 (pSer10) polyclonal antibody was obtained from Cell Signaling Technology (Danvers, MA, USA). Anti-phospho-specific PP1a (pThr320 in human PP1a) polyclonal antibody was a gift from Dr Angus C Nairn (The Rockefeller University, New York) (Kwon et al., 1997) . Anti-GST monoclonal antibody was purchased from Amersham Biosciences (Tokyo, Japan). Anti-glu and anti-myc monoclonal antibodies were gifts from Dr Larry A Feig (Tufts University, Boston). The anti-pan Aurora monoclonal antibody (K3-7) recognizes all of the human Aurora family, as described (Taguchi et al., 2002) . Polyclonal antibodies specific to PP1c isoforms have been described (Shima et al., 1993) . The peptides were synthesized and purified using HPLC by Dr Michael Berne (Tufts University Core Facility, Boston).
Plasmid constructs
Human TPX2 (1-43) (GenBankt accession number AB02704) was cloned by reverse transcription-ploymerase chain reaction (RT-PCR) of total RNA from DLD-1 colon cancer cells. Point mutations within Aurora-A were engineered by standard double PCR mutagenesis. All PCR-amplified cDNA products were fully sequenced to confirm mutations and to verify the absence of secondary point mutations. To create a mammalian expression vector, cDNA was inserted into an altered version of pMT3 that contained a modified glu (MEFMPME) 5 0 in the cloning site (Urano et al., 1996) . The plasmids, glu-Aurora-A/ pMT3, glu-Aurora-A(KN)/pMT3 glu-Aurora-B/pMT3, gluAurora-C/pMT3, myc-PP1a/pcDNA3, myc-PP1g1/pcDNA3, myc-PP1d/pcDNA3, pME4T-2, and Aurora-A/pME4T-2 have been described (Honda et al., 2000; Sugiyama et al., 2002; Taguchi et al., 2002; Li et al., 2004) . The short fragments of human Aurora-A (residues 281-293), Aurora-B (residues 225-237), and Aurora-C (residues 188-200) used as substrates were cloned into the pGEX4T-2 vector using sense and antisense oligonucleotides corresponding to the amino-acid sequences. A series of derivatives of human histone H3(5-15) fused with GST has been described (Sugiyama et al., 2002) .
Bacterial protein expression
For N-terminal His 6 -tagged recombinant Aurora-As, Aurora-A cDNAs were subcloned into pQE30 (Qiagen, Tokyo, Japan) and expressed in the bacterial strain M15 (pREP4). The fusion polypeptides were purified by Ni 2 þ -nitrilotriacetic acid chromatography (Qiagen). Human rAurora-B was obtained from coexpression with human IN-box, encoded in a modified pGEX6P-1 vector (Amersham Biosciences) as a bicistronic construct as follows. Human full-length Aurora B cDNA (Sugiyama et al., 2002) was subcloned with BamHI-EcoRI sites in the first cassette of the modified vector. The vector contains two cloning cassettes separated by a ribosomebinding site. Proteins expressed from the first cassette are C-terminal fusions to GST. The human C-terminal domain IN-box (amino acids 783-918) of INCENP (Li et al., 2004) was subcloned into the BglII-NotI sites of the second cassette. The resulting vector is referred to as pGEX6P-AB-rbs-INbox. Recombinant GST-fused proteins were produced in the E. coli BL21 strain (Stratagene, Tokyo, Japan) and purified with glutathione-Sepharose beads (Sigma-Aldrich, Tokyo, Japan). All recombinant proteins were dialysed against phosphatebuffered saline. Coomassie Brilliant blue R-250 staining of bands resolved on SDS-polyacrylamide gels determined the concentrations of recombinant proteins.
Phosphoamino acid analysis
We detected acid-stable phosphoamino acids as described (Duclos et al., 1991) . Briefly, GST-histone H3(5-15) was phosphorylated by rAurora-A in the presence of [g-32P]ATP. Proteins were subsequently separated by SDS-PAGE, electroblotted onto polyvinylidene difluoride membranes and detected by autoradiography. The radioactive band corresponding to 32 P-labeled GST-histone H3(5-15) was excised and the protein was hydrolysed in 6 M HCl for 1 h at 1101C. Liberated acid-stable phosphoamino acids were lyophilized and dissolved in water containing phosphorylated (p)Ser, pThr, and pTyr standards. The mixture was separated by electrophoresis at pH 1.9 (800 V Â h) in buffer containing 7.8% acetic acid and 2.5% formic acid (first dimension) followed by ascending chromatography in 2-methyl-1-propanol/formic acid/water (8:3:4) (v/v/v) (second dimension). After migration, the gels were dried, stained with ninhydrin, and radioactively labeled phosphoamino acids were detected by autoradiography.
Transient transfection COS-7 cells (3 Â 10 5 in 60 mm culture dishes) maintained in Dulbecco's modified Eagle's medium (DMEM; Sigma) containing 10% fetal calf serum (FCS; Sigma) at 371C in a 5% CO 2 atmosphere were transfected with mammalian expression vectors using DEAE-Dextran (Urano et al., 1996) .
Phospho-specific antibody generation
A synthetic threonine-phosphorylated human Aurora-A (residues 283-293; SSRRTpTLCGTLC) peptide was conjugated to maleimide-activated keyhole limpet hemocyanin (KLH; Pierce, Rockford, IL, USA) through a free C-terminal cysteine residue. New Zealand white rabbits were subcutaneously inoculated with 100 mg of immunogen and adjuvant on weeks 0, 2, 4, 6, 8, and 10 to generate anti-phospho-Thr288 Aurora-A polyclonal antibodies. Anti-sera were collected on weeks 7, 9, and 11 and pooled. Total immunoglobulin (Ig)G was isolated by Protein-A affinity chromatography (Amersham Biosciences) and then non-phospho-specific antibodies were removed by adsorption to the corresponding non-phosphorylated peptide conjugated to Affi-Gel 15 (Bio-Rad, Tokyo, Japan). Phospho-specific IgGs were purified by phosphophosphopeptide affinity chromatography.
Anti-phospho-Thr288 Aurora-A mouse monoclonal antibodies were generated by immunizing mice with KLH-conjugated phosphorylated peptide. Serum titers were monitored by immunoblotting using lysates of COS cells transfected with glu-Aurora-A/pMT3 in the absence or presence of nocodazole (400 ng/ml, 8 h). After several injections, splenic lymphocytes were fused to the myeloma cell line NS-1. Clonal populations of fusion cells were screened by enzyme-linked immunosorbent assays (ELISAs) for antibody production against phosphorylated peptide and non-phosphorylated peptide conjugated to maleimide-activated bovine serum albumin (Pierce) through a free C-terminal cysteine residue. Productive cells were cloned to monoclonal lines by serial dilution screening. Two monoclonal antibodies for phospho-Thr288 Aurora-A (pA7.2 and pA12.1) also detected proteins in immunoblots. Highly concentrated monoclonal antibodies were isolated from murine ascites after an intraperitoneal injection of hybridoma cells and then IgG was purified by Protein-A affinity chromatography.
Indirect immunofluorescence microscopy
HeLa cells were seeded on poly (D-lysine)-coated coverslips at B25% confluence. The cells were washed once on the following day with ice-cold phosphate-buffered saline (PBS) and fixed with methanol at À201C for 10 s. The cells were then washed three times with ice-cold PBS and incubated for 5 min at room temperature in PBS containing 0.05% Triton X-100. The permeabilized cells were washed three times with ice-cold PBS and then covered with PBS containing 10% bovine serum albumin and incubated for 30 min at room temperature. Diluted monoclonal antibody was placed on the coverslips and incubated for 45 min at 371C in a humidified chamber. After six PBS washes, the coverslips were covered with goat anti-mouse-Alexa 488 (Invitrogen, Tokyo, Japan) for 30 min in the dark at 371C in a humidified chamber. The coverslips were washed six times with PBS, mounted (mounting medium; Vector Laboratories, Burlingame, CA, USA) with 4 0 ,6-diamidino-2-phenylindole (DAPI) and attached to slides with clear nail polish.
Cell-cycle synchronization
Tissue culture dishes (10 cm) were seeded with 3 Â 10 6 exponentially growing HeLa cells and synchronized at S phase as follows. On the following day, thymidine (Sigma) was added to the medium to a final concentration of 2.5 mM. The plates were incubated for 16 h at 371C, washed three times with PBS, and then normal growth medium was added. After 8 h at 371C, the cells were exposed to thymidine for an additional 16 h. For M phase synchronization, cells were incubated with medium containing 400 ng/ml of nocodazole for 8 h. To monitor cellcycle distribution, the cellular DNA content was assayed by standard techniques using propidium iodide staining. Events were analysed using a FACScan (Becton Dickinson, Tokyo, Japan).
Immunoprecipitation
HeLa or transfected COS cells in 60-mm dishes were lysed by rocking in 500 ml of RIPA buffer (PBS with 0.1% SDS, 1% NP-40, 0.5% sodium deoxycholate, 1 mM phenylmethylsulfonyl fluoride, 10 mg/ml aprotinin, and 0.1 mM okadaic acid) for 15 min at 41C. The lysates were clarified by centrifugation at 16 500 g for 5 min, and then immunoprecipitated with primary monoclonal antibody bound to protein G-Sepharose (Amersham Biosciences) at 41C for 75 min. The beads were washed five times with 1 ml of RIPA buffer and finally resuspended in 15 ml of 2 Â SDS sample buffer. The precipitated proteins were separated by SDS-PAGE and then immunoblotted. Before immunocomplex kinase assays, glu-Aurora-A immunoprecipitates were washed twice with kinase buffer without dithiothreitol.
In vitro kinase assays Reaction mixtures (30 ml) containing substrates, enzymes, 50 mM ATP, and 3 mCi of [g-32 P]ATP in kinase activity buffer (20 mM Tris-HCl (pH 7.5), 10 mM MgCl 2 , 0.5 mM dithiothreitol, 0.1 mM EDTA) were incubated for 20 min at 301C. The reaction products separated by 12% SDS-polyacrylamide gel electrophoresis were visualized by Coomassie Brilliant blue R-250 staining. The gels were dried and then 32 P was detected using a MacBAS-1500 imaging analyser (Fuji Film).
Molecular imaging
Molecules were rendered from images using PyMOL software (Warren L DeLano, PyMOL Molecular Graphics System; http://pymol.sourceforge.net/). We applied the coordinates and structure factors for the surface models of human Aurora-A and Aurora-B from the Protein Data Bank (PDB codes: 1OL5 and 2BFY, respectively).
